Melazyme bets precision fermentation can make melanin and sweet protein a real business

Melazyme uses precision fermentation to produce high-value functional biomolecules — melanin and the sweet protein brazzein — for cosmetics, food, filtration and industrial applications.

That precision fermentation wins on function, not cost: melanin and brazzein with purity extraction and chemistry can't match, sold across cosmetics, food and materials.

$2M seed (May 2026) led by SeaX Ventures, with Stellaris Venture Partners and Plug and Play Ventures

Perumal Gandhi, who co-founded Perfect Day, and Bonney Oommen, its former chief product and strategy officer, founded Melazyme in 2025 in Utah. Their bet: precision fermentation should move past whey protein to molecules where fermentation's control over function creates obvious value, starting with melanin and the sweet protein brazzein.

Melazyme developed a patent-pending fermentation platform that produces melanin at over 99% purity — versus 70-80% from cuttlefish extraction and about 75% from chemical synthesis — plus a heat-stable brazzein advanced with commercial partners. In May 2026 it closed a $2M seed led by Bangkok-based SeaX Ventures, with Stellaris Venture Partners and Plug and Play Ventures participating, to fund platform development, production scale-up and early commercial deployment.

Melanin's 99%+ purity versus 70-80% from cuttlefish and 75% from chemistry gave Melazyme a hard, measurable advantage to sell against.

The founding team's Perfect Day experience meant the fermentation platform, strain selection and scale-up playbook already existed inside the company.

Melanin's metal-ion affinity opens follow-on markets — filtration, heavy-metal remediation, rare-earth recovery — beyond the near-term cosmetics revenue.

Brazzein's food-market runway lets the same platform serve two industries while the materials side matures.

Pick molecules where the new method beats incumbents on function, not price: melanin's 99% purity versus 70-80% from cuttlefish gave Melazyme a wedge extraction and chemistry can't copy.

As of September 2026 Melazyme is pre-commercial: the $2M seed is funding platform development, bioreactor scale-up and early deployments, with near-term revenue targeted at cosmetics and brazzein partnerships in food and beverage. The company projects the precision-fermentation market growing from about $20 billion today to over $70 billion by 2030, but its own production costs are not yet public.